United States Hypophosphatasia Treatment Market 2025 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

Global Hypophosphatasia Treatment Market reached US$ 841.9 million in 2023 and is expected to reach US$ 2785.10 million by 2031, growing at a CAGR of 16.1% during the forecast period 2024-2031

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/hypophosphatasia-treatment-market?sb

Key Development:

United States: Recent Developments

✅ In May 2025, Be Biopharma reported nonclinical data for its novel B‐cell therapy candidate BE-102 showing long-term production of active alkaline phosphatase (TNAP) after a single dose, offering a possible disease‐modifying alternative to frequent enzyme injections.

✅ In mid‐2025, a second‐generation enzyme replacement therapy Efzimfotase alfa (ALXN1850) entered Phase III clinical trials for HPP, aiming to reduce dosing frequency compared with existing therapy and improve treatment convenience for patients.

✅ In 2025, ongoing clinical‐trial updates show that the Phase III study of Efzimfotase alfa in adolescents and adults with HPP is "active, not recruiting," reflecting continued progress toward potential regulatory approval.

✅ In January 2025, a preclinical study of AAV8‐TNAP‐D10 demonstrated promising safety and efficacy in mouse models of HPP restoring bone and dental mineralization, supporting a potential "one‐shot" gene therapy for lifelong benefit.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=hypophosphatasia-treatment-market

Japan: Recent Developments

✅ In July 2025, researchers at Nippon Medical School presented at a national gene‐therapy conference a preclinical evaluation of a gene therapy drug for HPP (AAV‐TNAP), indicating advancing efforts toward clinical translation in Japan.

✅ In 2025, the trial registry for Japan shows a Phase III study CHESTNUT (ALXN1850 vs standard enzyme therapy) for pediatric HPP patients previously treated with enzyme replacement reflecting local efforts to evaluate next‐generation therapies in Japanese population.

✅ In 2025, a clinical‐case report in the Japanese medical literature described successful use of the standard therapy Asfotase alfa in an adult-onset HPP patient without obvious bone lesions highlighting continuing real-world clinical experience.

✅ In March 2025, a nationwide dental‐survey study of HPP patients in Japan revealed additional oral manifestations - beyond early tooth loss - such as poor tooth formation, malocclusion, and swallowing/feeding difficulties, underscoring the need for improved dental and skeletal care strategies alongside new therapies.

Key Players:

=> Purec Global, Alexion Pharmaceuticals, Inc, AM-Pharma B.V., Aastrom Biosciences, Inc, Rallybio, Biomarin, Pfizer Inc, Protalix Biotherapeutics, Sanofi among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/hypophosphatasia-treatment-market?sb

Key Segments:

By Type

Therapeutic Devices are segmented based on type, including electronic stimulators, infusion pumps, rehabilitation devices, respiratory therapy devices, and others. Electronic stimulators hold around 30% share, driven by applications in pain management, neurological rehabilitation, and physiotherapy. Infusion pumps account for 25%, fueled by adoption in hospitals and homecare for precise drug delivery. Rehabilitation devices represent 20%, supported by growing demand in orthopedic and neurological recovery. Respiratory therapy devices contribute 15%, driven by chronic respiratory disease management and increasing awareness of pulmonary care. Others make up 10%, including emerging therapeutic solutions and hybrid devices.

By Therapy Type

Pain Management Therapy leads with 30% share, supported by the prevalence of chronic pain conditions and growing demand for non-invasive treatments. Neurological Therapy accounts for 25%, driven by rehabilitation for stroke, Parkinson's, and other neurological disorders. Cardiopulmonary Therapy holds 15%, fueled by increasing cases of heart and lung diseases. Orthopedic Therapy represents 20%, supported by the rise in musculoskeletal disorders and post-surgical rehabilitation. Others contribute 10%, including metabolic and pediatric therapeutic interventions.

By End-User

Hospitals dominate with 55% share, driven by high patient volumes, comprehensive therapeutic services, and investment in advanced devices. Clinics & Rehabilitation Centers account for 25%, supported by specialized therapy programs and outpatient care adoption. Homecare Settings hold 15%, fueled by remote monitoring, home rehabilitation, and convenience of in-home therapy devices. Others represent 5%, including research institutes and specialty care centers.

By Region

North America - Largest Region (40% Share)
North America leads due to advanced healthcare infrastructure, high adoption of therapeutic devices, favorable reimbursement policies, and strong presence of key market players in the U.S. and Canada.

Europe - 25% Share
Europe holds 25%, supported by growing geriatric population, government initiatives in rehabilitation care, and adoption of innovative therapy devices in Germany, U.K., France, Italy, and Scandinavia.

Asia-Pacific - Fastest Growing Region (20% Share)
Asia-Pacific accounts for 20%, driven by rising prevalence of chronic diseases, expanding healthcare facilities, increasing awareness of rehabilitation therapies, and growing disposable income in China, India, Japan, and Southeast Asia.

South America - 10% Share
South America contributes 10%, fueled by hospital modernization, outpatient care expansion, and increasing adoption of therapeutic devices in Brazil, Argentina, and Chile.

Middle East & Africa - 5% Share
MEA represents 5%, supported by healthcare investments, rising chronic disease burden, and adoption of advanced therapeutic solutions in GCC countries, South Africa, and North African regions.

FAQ

What is the current size of the Hypophosphatasia Treatment Market?

A: In 2023, the Hypophosphatasia Treatment Market was valued at US$ 841.9 million , reflecting its strong industry presence.

Q2: How large is the Hypophosphatasia Treatment Market expected to be by 2031?

A: By 2031, industry forecasts suggest the Hypophosphatasia Treatment Market will grow to around US$ 2785.10 million, demonstrating significant expansion.

Q3: What is the growth rate of the Hypophosphatasia Treatment Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 16.1% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.